Epic endows three faculty positions at UW-Madison

Epic is giving generously to the University of Wisconsin-Madison this holiday season, endowing three faculty associate positions in the computer sciences department.

Epic's founder and CEO Judy Faulkner earned her master's degree in computer sciences from UW-Madison, and she was awarded an honorary doctorate from the university in 2010. In an article postedo on the department's website, she said the gift will help create a talent pool to fill technology jobs. The newly endowed positions will focus on teaching software development, application design and user interfaces.

"Computer scientists will be needed in almost every industry, and there is a significant shortage," Faulkner said. "Through this gift, the UW-Madison computer science faculty will educate more computer scientists to help fill current and future needs."

Already, many UW-Madison graduates work for Epic, with the vendor's campus located in a suburb of Madison.

"Here in the Madison area, Epic is our Microsoft," said Mark Hill, the chair of the computer sciences department at UW-Madison. "It's a huge tech giant right here in our backyard. We're grateful to Judy Faulkner for her longstanding support of our department."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.